Confirmed Panelists

  • Recommend
  • Tweet
  • Print
  • Email

Abbvie Biotech Ventures, Inc.—David Donabedian, PhD, Vice President

Action Potential Venture Capital—Juan-Pablo Mas, Partner

Alnylam Pharmaceuticals—John Maraganore, PhD, CEO

Avalanche Biotechnologies—Thomas W. Chalberg, PhD, Founder and CEO

Biotechnology Industry Organization—Cartier Esham, PhD, EVP, Emerging Companies

Caribou Biosciences—Rachel Haurwitz, PhD, President and CEO

Catalyst Pharmaceutical Partners—Patrick J. McEnany, Co-Founder, Chairman, President and CEO

Deerfield—Jonathan Leff, Partner, Chairman of the Deerfield Institute

EcoR1—Oleg Nodelmann, Co-Founder and Managing Director

Editas Medicine—Katrine S. Bosley, CEO

The Feinstein Institute for Medical Research—Christopher J. Czura, PhD, VP, Scientific Affairs, CFO, Elmezzi Graduate School of Molecular Medicine

Fenwick & West LLP—Effie Toshav, Partner

Forest Laboratories—Ellen Lubman, SVP Strategy and Innovation

GlobeImmune—Timothy C. Rodell, MD, CEO and President

GlycoMimetics—Rachel King, CEO (BIO, Chair)

Kite Pharma—David D. Chang, MD, PhD, EVP Research and Development, Chief Medical Officer

Knobbe Martens—Eli Loots, Partner

Morrison Foerster—Michael J. O'Donnell, Partner

MPM Capital—Todd Foley, Managing Director

NeuroPace—Martha J. Morrell, MD, Chief Medical Officer

Portola Pharmaceuticals—William Lis, CEO

RA Capital—Rajeev Shah, Portfolio Manager

Relypsa—John Orwin, President and CEO

Scioderm—Robert Ryan, MD, President and CEO

Takeda Ventures—Graeme Martin, President and CEO

Tocagen—Harry E. Gruber, MD, Chairman, CEO and President

ZIOPHARM Oncology—Jonathan Lewis, MD, PhD, CEO

As of September 4, 2014